OH Epic Formulary restricted to:

• Indication: Treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
• Service line: Oncology/Hematology
• Formulary location: Inpatient, Outpatient Infusion
• Service location: Inpatient, Outpatient Infusion
• Patient population: Adult
• Prior authorization required: Yes for outpatient
• Restriction/criteria of use (all will apply unless specified):
  • Relapsed or refractory multiple myeloma who received 2 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
  • Radiographically documented disease
  • Negative pregnancy test
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Healthcare facilities that dispense and administer ABECMA must be enrolled and comply with the REMS requirements.

• UpToDate
• Lexicomp
• DailyMed Package Inserts
• Johns Hopkins Guides